177 related articles for article (PubMed ID: 28073842)
21. [Active immunotherapy of prostate cancer with a focus on dendritic cells].
Thomas-Kaskel AK; Veelken H
Actas Urol Esp; 2007 Jun; 31(6):668-79. PubMed ID: 17896564
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effect of dendritic cells transfected with prostate-specific membrane antigen recombinant adenovirus on prostate cancer: An in vitro study.
Meng FD; Wang S; Jiang YH; Sui CG
Mol Med Rep; 2016 Mar; 13(3):2124-34. PubMed ID: 26783185
[TBL] [Abstract][Full Text] [Related]
23. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cells for specific cancer immunotherapy.
Meidenbauer N; Andreesen R; Mackensen A
Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216
[TBL] [Abstract][Full Text] [Related]
25. Adrenergic modulation of dendritic cell cancer vaccine in a mouse model: role of dendritic cell maturation.
Botta F; Maestroni GJ
J Immunother; 2008 Apr; 31(3):263-70. PubMed ID: 18317361
[TBL] [Abstract][Full Text] [Related]
26. Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells.
Eyrich M; Schreiber SC; Rachor J; Krauss J; Pauwels F; Hain J; Wölfl M; Lutz MB; de Vleeschouwer S; Schlegel PG; Van Gool SW
Cytotherapy; 2014 Jul; 16(7):946-64. PubMed ID: 24831836
[TBL] [Abstract][Full Text] [Related]
27. Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines.
Dobrovolskienė N; Pašukonienė V; Darinskas A; Kraśko JA; Žilionytė K; Mlynska A; Gudlevičienė Ž; Mišeikytė-Kaubrienė E; Schijns V; Lubitz W; Kudela P; Strioga M
Vaccine; 2018 Jul; 36(29):4171-4180. PubMed ID: 29895501
[TBL] [Abstract][Full Text] [Related]
28. Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro.
Saito H; Kitagawa K; Yoneda T; Fukui Y; Fujsawa M; Bautista D; Shirakawa T
Cancer Gene Ther; 2017 Jul; 24(7):289-296. PubMed ID: 28621316
[TBL] [Abstract][Full Text] [Related]
29. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.
Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP
J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis.
Draube A; Klein-González N; Mattheus S; Brillant C; Hellmich M; Engert A; von Bergwelt-Baildon M
PLoS One; 2011 Apr; 6(4):e18801. PubMed ID: 21533099
[TBL] [Abstract][Full Text] [Related]
31. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
[TBL] [Abstract][Full Text] [Related]
32. Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.
Schreibelt G; Bol KF; Westdorp H; Wimmers F; Aarntzen EH; Duiveman-de Boer T; van de Rakt MW; Scharenborg NM; de Boer AJ; Pots JM; Olde Nordkamp MA; van Oorschot TG; Tel J; Winkels G; Petry K; Blokx WA; van Rossum MM; Welzen ME; Mus RD; Croockewit SA; Koornstra RH; Jacobs JF; Kelderman S; Blank CU; Gerritsen WR; Punt CJ; Figdor CG; de Vries IJ
Clin Cancer Res; 2016 May; 22(9):2155-66. PubMed ID: 26712687
[TBL] [Abstract][Full Text] [Related]
33. Generation of immature autologous clinical grade dendritic cells for vaccination of cancer patients.
Toungouz M; Quinet C; Thille E; Fourez S; Pradier O; Delville JP; Velu T; Lambermont M
Cytotherapy; 1999; 1(6):447-53. PubMed ID: 20426545
[TBL] [Abstract][Full Text] [Related]
34. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables.
Michael A; Ball G; Quatan N; Wushishi F; Russell N; Whelan J; Chakraborty P; Leader D; Whelan M; Pandha H
Clin Cancer Res; 2005 Jun; 11(12):4469-78. PubMed ID: 15958632
[TBL] [Abstract][Full Text] [Related]
35. Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.
Scheid E; Major P; Bergeron A; Finn OJ; Salter RD; Eady R; Yassine-Diab B; Favre D; Peretz Y; Landry C; Hotte S; Mukherjee SD; Dekaban GA; Fink C; Foster PJ; Gaudet J; Gariepy J; Sekaly RP; Lacombe L; Fradet Y; Foley R
Cancer Immunol Res; 2016 Oct; 4(10):881-892. PubMed ID: 27604597
[TBL] [Abstract][Full Text] [Related]
36. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele.
Iwami K; Shimato S; Ohno M; Okada H; Nakahara N; Sato Y; Yoshida J; Suzuki S; Nishikawa H; Shiku H; Natsume A; Wakabayashi T
Cytotherapy; 2012 Jul; 14(6):733-42. PubMed ID: 22424217
[TBL] [Abstract][Full Text] [Related]
37. Dendritic cell vaccination in melanoma patients: From promising results to future perspectives.
Boudewijns S; Bloemendal M; Gerritsen WR; de Vries IJ; Schreibelt G
Hum Vaccin Immunother; 2016 Oct; 12(10):2523-2528. PubMed ID: 27322496
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.
Lesterhuis WJ; De Vries IJ; Schreibelt G; Schuurhuis DH; Aarntzen EH; De Boer A; Scharenborg NM; Van De Rakt M; Hesselink EJ; Figdor CG; Adema GJ; Punt CJ
Anticancer Res; 2010 Dec; 30(12):5091-7. PubMed ID: 21187495
[TBL] [Abstract][Full Text] [Related]
39. Immunostimulatory CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic T cell responses.
Maurer T; Pournaras C; Aguilar-Pimentel JA; Thalgott M; Horn T; Heck M; Heit A; Kuebler H; Gschwend JE; Nawroth R
Urol Oncol; 2013 Oct; 31(7):1395-401. PubMed ID: 21982682
[TBL] [Abstract][Full Text] [Related]
40. [Clinical efficacy and relative factors of dendritic cell-based tumor vaccination for prostate cancer: a systematic review and meta-analysis].
Wu K; Meng JS; Baihetiya A; Wang YJ
Zhonghua Nan Ke Xue; 2013 Jun; 19(6):545-50. PubMed ID: 23862236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
